Back to News
Market Impact: 0.25
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
Source: Business Wire
Patents & Intellectual PropertyHealthcare & BiotechTechnology & Innovation
bioAffinity Technologies received a notice of allowance for a new patent in Japan covering CyPath Lung, its noninvasive lung cancer diagnostic test. The patent allowance is a positive intellectual-property development, but the article provides no financial figures or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BIAF0.75
More News
- Israel’s economy prospers despite years of war, but prices worry voters
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- What's behind the recovery rally in tech stocks — plus, Elon Musk's very good week
- Why is T-Mobile stock tumbling today?
- Elon Musk intensifies attack on Ambani over Starlink India launch delay
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund